1. Products
  2. Vaccines
  3. Prestige® Prodigy®
View Product label
Vaccine
Prestige® Prodigy®
Indications

This product has been shown to be effective for the vaccination of healthy horses 6 months of age or older against abortion and respiratory disease caused by EHV-1. Duration of immunity has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.

Purpose
Science
Administration

The Science of Advanced

  • EHV-1, or rhino, can cause respiratory tract infections, epidemic abortions in mares, the birth of non-viable foals and sporadic neurological disease. This vaccine does not have a label claim for neurological disease protection.
  • An inactivated, purified, concentrated, adjuvanted, tissue culture origin, equine herpesvirus EHV-1 vaccine
  • Exceptional safety profile with the smooth Havlogen® adjuvant
  • Advanced filtration process through the Antigen Purification System (APS™)

Science

1. In a severe EHV-1 challenge study, Prestige® Prodigy®-vaccinated mares demonstrated a 96.1% reduction in virus shedding from nasal exudates1

2. In an independent research study, Prestige®Prodigy® produced a statistically significant EHV-1 antibody response (VN antibody titers)2 compared to unvaccinated animals

3. In an independent research study, Prestige®Prodigy® produced a statistically significant IFN-𝛾 response2 compared to unvaccinated animals

  • ‐ Cytokine, ie: IFN-𝛾 response, can be a useful surrogate for quantifying cytotoxic lymphocyte responses3, shown to be a measure of cell-mediated protective immunity (CMI) to EHV-1 infection4


1 Intervet Research Data.

2 Holmes MA, Townsend HGG, Sussey S, Breathnach C, Barnett C, Holland RE, Lunn DP: Immune responses to commercial equine vaccines. AAEP Proceedings, Vol. 49, 2003.

3 Murali-Krishna K, Altman JD, Suresh M, et al. In vivo dynamics of anti‐viral DC8 T cell responses to different epitopes. Adv Exp Med Biol 1998; 452:123‐142

4 O'Neil T, Kydd JH, Allen GP, et al. Determination of equid herpesvirus 1 specific, CD8+ cytotoxic T lymphocyte precursor frequecies in ponies. Vet Immunal Immunopathol 1999; 70:43-54.

* Adjuvant - Intervet's proprietary technology.


ADDITIONAL RESOURCES

Administration

Dose:

For pregnant mares administer a 2 mL dose intramuscularly in the 5th, 7th and 9th months of pregnancy. Three doses are essential for primary immunization. Maiden and barren mares housed or pastured with pregnant mares should be vaccinated on the same schedule. For primary vaccination against respiratory disease administer three 2 mL doses intramuscularly at 4 to 6 week intervals. Historically, annual revaccination with this product has been recommended. The need for this booster has not been established. For more information on revaccination frequency, consult your veterinarian.